(NASDAQ: CSBR) Champions Oncology's forecast annual revenue growth rate of 17.97% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.07%.
Champions Oncology's revenue in 2026 is $58,424,000.On average, 3 Wall Street analysts forecast CSBR's revenue for 2026 to be $829,013,662, with the lowest CSBR revenue forecast at $796,491,887, and the highest CSBR revenue forecast at $853,384,164. On average, 3 Wall Street analysts forecast CSBR's revenue for 2027 to be $924,398,835, with the lowest CSBR revenue forecast at $888,155,525, and the highest CSBR revenue forecast at $951,588,262.
In 2028, CSBR is forecast to generate $1,332,045,822 in revenue, with the lowest revenue forecast at $1,279,805,463 and the highest revenue forecast at $1,371,219,147.